Last reviewed · How we verify

BMS-986489 — Competitive Intelligence Brief

BMS-986489 (BMS-986489) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-1β inhibitor. Area: Inflammation.

phase 2 IL-1β inhibitor IL-1β Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

BMS-986489 (BMS-986489) — SCRI Development Innovations, LLC. BMS-986489 is an anti-inflammatory agent.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BMS-986489 TARGET BMS-986489 SCRI Development Innovations, LLC phase 2 IL-1β inhibitor IL-1β
Canakinumab Injection canakinumab-injection Pfizer marketed Monoclonal Antibody IL-1β
Ilaris® Ilaris® AO GENERIUM marketed IL-1β inhibitor (monoclonal antibody) IL-1β (Interleukin-1 beta)
Ziltivekimab B Ziltivekimab B Novo Nordisk A/S phase 3 IL-1β inhibitor IL-1β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-1β inhibitor class)

  1. Uniquity One (UNI) · 2 drugs in this class
  2. Novo Nordisk A/S · 1 drug in this class
  3. SCRI Development Innovations, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMS-986489 — Competitive Intelligence Brief. https://druglandscape.com/ci/bms-986489. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: